Realtime | Geld | Brief | Zeit |
---|---|---|---|
11,240 | 11,320 | 01.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 59 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
29.04. | Devyser Q1 2025 slides reveal mixed results with 8% growth, EBIT challenges | 1 | Investing.com | ||
29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 321 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 154 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 201 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 282 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 176 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 691 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 135 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen | |
23.07.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2024 | 174 | GlobeNewswire (Europe) | "Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large tenders during the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDTRONIC | 74,86 | -0,53 % | Dividendenbekanntmachungen (27.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,6216 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1795 EUR ALICO INC US0162301040 0... ► Artikel lesen | |
HCA HEALTHCARE | 331,00 | +2,89 % | Here's What to Expect From HCA Healthcare's Next Earnings Report | ||
LANTHEUS | 69,06 | +2,46 % | Lantheus Holdings, Inc.: Lantheus Announces Sale of SPECT Business to SHINE Technologies | Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®... ► Artikel lesen | |
AMEDISYS | 83,50 | +1,83 % | Proposed Medicare payment cut for home health could scuttle UnitedHealth/Amedisys deal | ||
ENVISTA | 16,700 | -1,76 % | Hitachi Digital Services Announces Five-Year Strategic IT Partnership with Envista | DALLAS, May 15, 2025 /PRNewswire/ -- Hitachi Digital Services, the digital consultancy and technology services subsidiary of Hitachi, Ltd. (TSE: 6501), today... ► Artikel lesen | |
CAREDX | 16,285 | +1,84 % | CareDx, Inc.: CareDx gibt Studie bekannt, die zeigt, dass AlloSeq cfDNA bei der Erkennung von Abstoßungsreaktionen bei Organtransplantationspatienten äußerst genau ist | AlloSeq cfDNA entspricht der Leistung des bewährten AlloSure-Tests CareDx bringt mit AlloSeq cfDNA ein innovatives nicht-invasives Transplantationsmonitoring für Patienten auf internationaler... ► Artikel lesen | |
SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Third Quarter 2025 Results | Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow
HENDERSON... ► Artikel lesen | |
GT BIOPHARMA | 3,500 | -2,23 % | GT Biopharma, Inc. - S-1/A, General form for registration of securities | ||
CARMAT | 0,329 | +2,17 % | XFRA CXT: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCARMAT EO -,04 CXT... ► Artikel lesen | |
CHEMOMETEC | 75,65 | +0,20 % | Chemometec A/S: Preliminary revenue figures for the 2024/25 financial year | ANNOUNCEMENT NO. 290 1 July 2025 Preliminary revenue figures for the 2024/25 financial year Based on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 496 million... ► Artikel lesen | |
ARRAIL GROUP | 0,216 | -1,82 % | ARRAIL GROUP (06639): CONNECTED TRANSACTION IN RELATION TO AMENDMENT TO THE LOAN AGREEMENT AND PLEDGE OF SHARES BY THE CONTROLLING SHAREHOLDER | ||
POLAREAN IMAGING | 0,019 | 0,00 % | Polarean Imaging PLC - Promotion & sales representative agreement | ||
PROMIMIC | 1,580 | -1,86 % | Curiteva & Promimic - Bonded by Innovation | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,920 | -0,30 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen auf "Buy" mit einem Kursziel von 60 Euro belassen. Julien Dormois fasste in einer am Donnerstag... ► Artikel lesen | |
FRESENIUS | 42,640 | -0,14 % | Aktienmarkt: Fresenius SE & Co. KGaA-Aktie kann sich nicht behaupten (42,16 €) | Der Anteilsschein von Fresenius SE & Co. KGaA notiert am Mittwoch leichter. Die Aktie kostete zuletzt 42,16 Euro. Für Inhaber von Fresenius+Co KgaA ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen |